

| Indication | EudraCT/CT.gov Number | Trial Short Desc | Start Date | Phase | Development Name | Summary/Results |
|-------------------------|-----------------------|---|------------|------------|--------------------|-----------------|
| Atopic Dermatitis | NCT06526182 | Treatment in Adults and Adolescents With Moderate-to-Severe Atopic De | 03/07/2024 | Phase IIIb | Lebrikizumab | NOT AVAILABLE |
| Actinic Keratosis | NCT06135415 | Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Act | 21/12/2023 | Phase III | Tirbanibulin | NOT AVAILABLE |
| Atopic Dermatitis | NCT05990725 | Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adoles | 20/11/2023 | Phase 3B | Lebrikizumab | NOT AVAILABLE |
| Atopic Dermatitis | NCT05916365 | Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant W | 23/05/2023 | Phase III | Lebrikizumab | NOT AVAILABLE |
| Actinic Keratosis | NCT05387525 | Treatment of Adult Participants With Actinic Keratosis on the Face or Scal | 24/10/2022 | Phase IV | Tirbanibulin | NOT AVAILABLE |
| Actinic Keratosis | NCT05279131 | Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants W | 28/06/2022 | Phase III | Tirbanibulin | NOT AVAILABLE |
| Atopic Dermatitis | 2021-002967-23 | Cyclosporine failure Phase III study | 25/01/2022 | Phase III | Lebrikizumab | NOT AVAILABLE |
| Nail Psoriasis | H1902 | Effectiveness of Tildra in nail/pso patients in RWC - TINAIL | 16/10/2020 | Phase IV | Lor Ilumetri | NOT AVAILABLE |
| Muscle Spasm | | Spasticity control with Sativex® in patients with MSS in AU | 09/06/2020 | Phase IV | Lor SATIVEX | NOT AVAILABLE |
| Psoriasis | 2019-003218-15 | MODIFY - Disease-modifying effect of long-term treatment | 29/01/2020 | Phase IV | Glc Ilumetri | AVAILABLE |
| Psoriasis Plaque | 2019-002804-42 | TRIBUTE (Quality of Life 100mg) | 17/12/2019 | Phase IV | Glc Ilumetri | AVAILABLE |
| Psoriasis | NCT04203693 | SAIL | 30/10/2019 | Phase IV | Glc Ilumetri | NOT AVAILABLE |
| Psoriasis | 2019-000817-35 | Transition DMF to Tildrakizumab | 04/09/2019 | Phase IV | Glc Ilumetri | AVAILABLE |
| Psoriasis | UPSIL | UPSIL-SKILarence in plaque pso pts meeting Upgrade criteria | 15/08/2019 | Phase IV | Lor LAS190046 | NOT AVAILABLE |
| Psoriasis | 2018-004010-18 | Efficacy and safety of DMF in plaque Pso patients. MODERATES | 06/08/2019 | Phase IV | Lor LAS190046 | NOT AVAILABLE |
| Psoriasis | 2018-004010-18 | Moderate exploratory Sub Study | 06/08/2019 | Phase IV | Glc LAS190046 | NOT AVAILABLE |
| Multiple Sclerosis | M/SATIVX/08 | Sativex and Goal Attainment Scales - GAS Study | 28/03/2019 | Phase IV | Glc SATIVEX | AVAILABLE |
| Psoriasis | T1801 | TILOT - Tildrakizumab (Ilumetri) in Long-Term Treatment | 08/01/2019 | Phase IV | Lor Ilumetri | NOT AVAILABLE |
| Multiple Sclerosis | SATKAM | Evaluación del dispositivo de administración de Sativex | 08/10/2018 | Phase IV | Glc SATIVEX | AVAILABLE |
| Psoriasis | 2017-003818-11 | DIMESKIN2 | 31/05/2018 | Phase IIIb | Lor LAS190046 | NOT AVAILABLE |
| Psoriasis | SKILL | SKILL – SKILarence® in Long-Term Treatment | 31/01/2018 | Phase IV | Lor LAS190046 | NOT AVAILABLE |
| Multiple Sclerosis | NIS-BE | Retrospective data collection on MS patients in Belgium | 01/01/2018 | Phase IV | Lor SATIVEX | AVAILABLE |
| Psoriasis | 2017-001368-40 | DIMESKIN 1 | 06/10/2017 | Phase IV | Lor LAS190046 | AVAILABLE |
| Atopic Dermatitis in Pr | M/000MO/02 | Monovo in AD in children | 31/01/2017 | Phase IV | Glc MOMETASONE FU | AVAILABLE |
| Multiple Sclerosis | M/SATIVX/05 | TASTE study_Palatability and oral cavity tolerability | 21/09/2016 | Phase IV | Glc SATIVEX | AVAILABLE |
| Androgenetic Alopecia | 2015-002877-40 | Efficacy and Safety of P-3074 Topical Solution | 02/08/2016 | Phase III | P-3074 (Finasterid | AVAILABLE |
| Multiple Sclerosis | M/SATIVX/06 | ADL study_Sativex in Activity Daily Living | 25/07/2016 | Phase IV | Glc SATIVEX | AVAILABLE |
| Multiple Sclerosis | ESTEEM | Retrospective study-MS resistant spasticity p.(ESTEEM study) | 01/05/2016 | Phase IV | Lor SATIVEX | AVAILABLE |
| Multiple Sclerosis | 2015-004451-40 | Sativex as add-on therapy vs. further optimized first-line | 25/04/2016 | Phase IV | Glc SATIVEX | AVAILABLE |
| Nail Psoriasis | 2015-002365-34 | Efficacy, safety and tolerability of topical P-3073 | 23/11/2015 | Phase III | P-3073 (Calcipotri | AVAILABLE |
| Actinic Keratosis | SEQ TREAT AT | NIS Sequential Treatment Actikerall + Solaraze | 15/10/2015 | Phase IV | Lor ACTIKERALL | AVAILABLE |

| Indication | EudraCT/CT.gov Number | Trial Short Desc | Start Date | Phase | Development Name | Summary/Results |
|--------------------|-----------------------|--|------------|-----------|---------------------|---------------------------|
| Onychomycosis | 2015-000561-31 | Efficacy and Safety of P-3058 10% Nail Sol. in Onychomycosis | 20/08/2015 | Phase III | P-3058 (terbinafin) | NOT AVAILABLE |
| Actinic Keratosis | 2014-001171-31 | Field-Directed Treatment Of Actinic Keratoses Grade I to II | 17/10/2014 | Phase III | ACTIKERALL | AVAILABLE |
| Onychomycosis | 2013-005595-17 | Paediatric trial on onychomycosis | 26/08/2014 | Phase II | P-3058 (terbinafin) | AVAILABLE |
| Psoriasis Plaque | 2013-003757-22 | Antipsoriatic efficacy and safety of LAS41004 | 02/06/2014 | Phase IIa | LAS41004 | AVAILABLE |
| Psoriasis Plaque | 2013-003754-24 | Anti-psoriatic efficacy of LAS41004 formulations | 24/02/2014 | Phase IIa | LAS41004 | AVAILABLE |
| Nail Psoriasis | 2013-004519-28 | A phase II trial to evaluate the anti-psoriatic efficacy | 07/02/2014 | Phase II | LAS41006 | AVAILABLE |
| Psoriasis Plaque | 2012-000055-13 | Efficacy and Safety of LAS41008 vs LASW1835 and vs Placebo | 18/01/2013 | Phase III | LAS190046 | AVAILABLE |
| Multiple Sclerosis | 2011-002258-30 | Sativex on Spasticity in Progressive MS | 19/04/2012 | Phase III | SATIVEX | AVAILABLE |
| Psoriasis Plaque | 2011-000186-13 | Different formulations of LAS41004 in psoriasis plaque test | 02/05/2011 | Phase II | LAS41004 | AVAILABLE |
| Actinic Keratosis | 2010-022980-37 | Efficacy of LAS41005 compared to cryotherapy | 13/04/2011 | Phase II | LAS41005 | AVAILABLE |
| Psoriasis | 2010-022281-27 | Efficacy of LAS41004 in different formulations | 10/01/2011 | Phase II | LAS41004 | AVAILABLE |
| Actinic Keratosis | 2010-022244-20 | Efficacy and safety of LAS41007 in actinic keratosis | 11/11/2010 | Phase III | LAS41007 | AVAILABLE |
| Psoriasis Plaque | 2010-018355-10 | Different concentrations in psoriasis plaque test | 28/06/2010 | Phase II | LAS41004 | AVAILABLE |
| Psoriasis Plaque | 2009-016629-33 | Efficacy of LAS41002 lotion in a psoriasis plaque test | 22/02/2010 | Phase II | MOMETASONE FU | AVAILABLE |
| Atopic eczema | 2009-017407-28 | Mometasone/LAS41002 in atopic eczema | 10/02/2010 | Phase II | MOMETASONE FU | AVAILABLE |
| Tinea pedis | 2009-016626-14 | Antimicrobial efficacy of topical octenidine/prednicarbonate | 03/02/2010 | Phase IIa | LAS41003 | AVAILABLE |
| Tinea pedis | 2009-016626-14 | Treatment Efficacy& Safety of Inflammatory Tinea Pedis | 01/02/2010 | Phase II | LAS41003 | AVAILABLE |
| Scalp Psoriasis | 2009-016261-28 | Efficacy of LAS41002 lotion in scalp psoriasis | 07/01/2010 | Phase IIb | MOMETASONE FU | AVAILABLE |
| Infected Eczema | 2009-011931-11 | Efficacy and Safety of topically applied LAS41003 | 06/11/2009 | Phase II | LAS41003 | AVAILABLE |
| Actinic Keratosis | 2009-012063-33 | LAS41007 vs. Solaraze in actinic keratosis I&II | 12/08/2009 | Phase II | LAS41007 | AVAILABLE |
| Infected Eczema | 2009-009948-23 | Antimicrobial efficacy of topical LAS41003 in exp.flora test | 02/06/2009 | Phase IIa | LAS41003 | AVAILABLE |
| Infected Eczema | 2008-003362-26 | Antimicrobial efficacy of topical octenidine/prednicarbonate | 29/09/2008 | Phase IIa | LAS41003 | AVAILABLE |
| Psoriasis | 2008-002141-24 | Anti-psoriatic efficacy in a psoriasis plaque test | 23/06/2008 | Phase II | MOMETASONE FU | AVAILABLE |
| Actinic Keratosis | 2007-003889-18 | Verrumal vs. placebo vs. Solaraze in Actinic Keratosis I/II | 05/06/2008 | Phase III | LAS41005 | AVAILABLE |
| Psoriasis Plaque | 2007-001793-87 | Efficacy and Safety of LAS37779 1% Cream in Plaque Psoriasis | 03/08/2007 | Phase IIa | LAS37779 | AVAILABLE |
| Actinic Keratosis | 2006-005432-24 | Efficacy and tolerability of Verrumal in actinic keratosis | 19/04/2007 | Phase II | LAS41005 | AVAILABLE |
| Rosacea | 2006-002410-35 | Isotretinoin versus doxycycline in the treatment of rosacea | 13/02/2007 | Phase II | Isotretinoin | AVAILABLE |
| Psoriasis Plaque | 2006-001126-90 | Curatoderm in plaque psoriasis | 01/09/2006 | Phase III | tacalcitol | AVAILABLE |
| Psoriasis Plaque | 2005-003162-42 | Efficacy, safety and tolerability of 1% LAS37779 cream | 03/11/2005 | Phase IIa | LAS37779 | AVAILABLE |
| Verrucea vulgaris | 2005-001593-26 | Verrucea vulgaris in organtransplant recipients | 10/08/2005 | Phase IV | Glc LAS41005 | AVAILABLE |